Dahan Michel

Akebia Therapeutics, Inc.

SVP, Chief Operating Officer

Avg. Two Year Performance

No Purchase Track Record

44% Avg. Sale Return 20% Compound

Holdings: 672.09K shares

Last Three Months: 23-Aug-24 -- 22-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Biotechnology

Drugs

Two Year Chart

23-Nov-22 -- 22-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions